5 Most Promising Cancer Stocks According to Analysts

3. Fate Therapeutics, Inc. (NASDAQ:FATE)

Latest Analyst Share Price Upside: 109.93%

Fate Therapeutics, Inc. (NASDAQ:FATE) develops treatments for lymphoma, myeloma, and solid tumors. It has performed well financially as of late by having beaten analyst EPS estimates in all four of its latest quarters. The shares are rated Buy on average, and the average share price target is $6.34.

Insider Monkey dug through 910 hedge fund portfolios for this year’s September quarter and discovered 24 Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders. Jeremy Green’s Redmile Group was the biggest investor through its $27.8 million investment.

Follow Fate Therapeutics Inc (NASDAQ:FATE)